Baird analyst Brian Skorney lowered the price target on Alto Neuroscience (NYSE: ANRO) to $10.00 (from $32.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

After-hours movers: McDonald's, Starbucks, Seagate, Alto Neuroscience and moreOctober 22, 2024 4:44 PM Form 8-K Alto Neuroscience, Inc. For: Oct 22October 22, 2024 4:35 PM Alto Neuroscience (ANRO) Reports Topline Results from a Phase 2b Trial of ALTO-100 October 22, 2024 4:30 PM Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive DisorderOctober 22, 2024 4:30 PM Form SC 13G Alto Neuroscience, Inc. Filed by: BlackRock, Inc.October 21, 2024 4:13 PM